Fiscal 2022 Third Quarter Highlights
Net sales of $74.0 million increased 3.9% compared to the prior-year quarter
Med Tech grew 28.6% and Med Device declined 2.8% year over year
Gross margin of 52.2% declined 190 basis points year over year
GAAP loss per share of $0.13 and adjusted earnings per share of $0.03
Subsequent to quarter end:
the Company enrolled the first patients in its PRESERVE study for the use of NanoKnife in prostate;
the Company received FDA approval for its AlphaVac F18 thrombectomy system; and
the Company received FDA approval for its IDE study for the use of AlphaVac F18 to treat pulmonary embolism
- https://finance.yahoo.com/news/angiodynamics-reports-fiscal-2022-third-110000276.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.